U.S. FDA approves new non-opioid dual-acting analgesic Zynrelef

Heron Therapeutics recently announced that the U.

In the first 3 days after surgery, patients usually experience the most severe postoperative pain, and many patients need opioids to control their pain.

In the European Union, Zynrelef was approved in September 2020 for the treatment of postoperative pain caused by small and medium surgical wounds in adults.

It is understood that Zynrelef (HTX-011) is a new, non-opioid analgesic, which is composed of the local anesthetic bupivacaine and the low-dose non-steroidal anti-inflammatory drug meloxicam A dual-acting, fixed-dose combination product, specially designed for a single administration at the surgical site to treat postoperative pain and inflammation.

It is worth mentioning that Zynrelef is the first and only postoperative pain management therapy that has been rigorously tested in the Phase 3 study and proved to be significantly better than bupivacaine solution.

Note: The original text has been deleted

Original source: Heron Therapeutics Announces US FDA approval of ZYNRELEF (HTX-011) for the Management of Postoperative Pain for up to 72 Hours

This article is from Bio Valley, for more information, please download the Bio Valley APP (